Categorized | Stock Profiles

BSGM (BioSig Technologies Inc.)

Share Button

BSGMBioSig Technologies Inc. (BSGM) is a U.S. based medical device company that is developing a proprietary technology platform to improve the electrophysiology market.

Electrophysiology (EP) is a cardiology specialty that diagnoses and treats heart arrhythmias or problems related to the heart’s electrical system such as the heart beating too fast, slow, or irregular. Sometypes of arrhythmias require a medical procedure called a catheter ablation to place a series of thin flexibles wires (catheters) into the blood vessel when medicine cannot control the irregulation. However, this specific diagnosis of the heart is not always easily obtained today.

Aiming to improve the market, BSGM’s Pure EP System is designed to obtain and display precise, real-time cardiac evaluation and information during the electrophysiology study and ablation procedure that will deliver high-quality cardiac signal recordings and successfully integrate with other advanced electrophysiology equipment. By providing clarity of the data, BSGM’s Pure EP System can guide electrophysicians in efficiently identifying the target areas of the tissue creating the heart rhythm disturbance, shorten and simplify EP procedures, and minimize the need for repeat ablation procedures.

Currently, BSGM is performing preclinical studies at the Mayo Clinic in Minnesota and is collaborating with several of prestigious cardiac arrhythmia centers in the U.S. including University of California Los Angeles (UCLA) Cardiac Arrhythmia Center and Texas Cardiac Arrhythmia Institute.




Market Outlook:

  • The electrophysiology market is valued at $3 billion and growing.
  • Cardiac arrhythmias is a heart disease currently affecting 14.4 million Americans.
  • Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) are two of the deadliest types of cardiac arrhythmia’s today.
  • VT accounts for 350,000 sudden cardiac deaths per year in the U.S.
  • According to the American Heart Association, AF increases the risk of a stroke, the 4th leading U.S. cause of death, four to five-fold and causes 600,000 hospitalizations per year.
  • Approximately 8 – 12 million Americans will have AF by 2050.
  • AF has an estimated annual cost of $26 billion
  • The electrophysiology devices market is one of the world’s fastest growing market segments
  • Market analysts predict the global market for electrophysiology devices will grow at a 12.1% CAGR and will total $5.5 billion by 2019.
  • Analysts also predict the number of complex AF &VT procedures will grow 10.5% annually to 160,000 cases by 2017.


Recent News:

This post was written by:

- who has written 2169 posts on StockRockandRoll.

Contact the author

Comments are closed.

© 2020 MJ Capital, LLC | All rights reserved